Opus Genetics (IRD) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.27% |
| Dec 31, 2025 | -47.25% |
| Sep 30, 2025 | 5.78% |
| Jun 30, 2025 | 23.18% |
| Mar 31, 2025 | 71.80% |
| Dec 31, 2024 | 115.35% |
| Jun 30, 2024 | 44.56% |
| Mar 31, 2024 | 8.76% |
| Dec 31, 2023 | 23.43% |
| Sep 30, 2023 | 15.28% |
| Jun 30, 2023 | 39.71% |
| Mar 31, 2023 | 283.81% |
| Dec 31, 2022 | -46.88% |
| Sep 30, 2022 | -15.34% |
| Jun 30, 2022 | 9.09% |
| Mar 31, 2022 | 10.16% |
| Dec 31, 2021 | -18.25% |
| Sep 30, 2021 | -41.18% |
| Jun 30, 2021 | -39.27% |
| Mar 31, 2021 | 7.57% |
| Dec 31, 2020 | -11.33% |
| Sep 30, 2020 | 22.28% |
| Jun 30, 2020 | 3.05% |
| Mar 31, 2020 | 1.63% |
| Dec 31, 2019 | -19.00% |
| Sep 30, 2019 | -11.08% |
| Jun 30, 2019 | -0.75% |
| Mar 31, 2019 | 4.64% |
| Dec 31, 2018 | -68.35% |
| Sep 30, 2018 | 32.97% |
| Jun 30, 2018 | 37.49% |
| Mar 31, 2018 | -4.43% |
| Dec 31, 2017 | 54.95% |
| Sep 30, 2017 | 30.30% |
| Jun 30, 2017 | 41.52% |
| Mar 31, 2017 | 24.65% |
| Dec 31, 2016 | 59.94% |
| Sep 30, 2016 | 21.23% |
| Jun 30, 2016 | 15.59% |
| Mar 31, 2016 | 11.17% |
| Dec 31, 2015 | 23.45% |
| Sep 30, 2015 | -30.00% |